NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Insulin Resistance in Egyptian Patients With Multiple Sclerosis

Not Yet RecruitingN/A

Sponsor: Assiut University

Conditions: Multiple Sclerosis, Insulin Resistance

Interventions: treatment of insulin resistance with appropriate modality according to each patient

The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer are: 1. what is the prevalence of insult resistance among Egyptian patients with Multiple sclerosis? 2. what are the effects of insulin resistance on multiple sclerosis disease activity and progression 3. what are the effects of treating insulin resistance on multiple sclerosis disease activity and progression participants with MS will be tested for IR to determine its prevalence, in the 2nd phase a group of MS patients with IR will be compared with another control group of MS patients without IR for clinical, laboratory, and radiological markers of disease activity and progression twice at baseline and after 1 year. in the 3rd phase, patients with IR will be divided into 2 groups one who will receive appropriate treatment for IR and the other group without treatment of IR and will be compared by the end of the 2nd year for clinical, laboratory and radiological markers of disease activity and progression

Eligibility overview

Sex: ALL

Age: 18 Years to 50 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* seventy patients aged 18-50 years old of both sex fulfilling the revised McDonald's Criteria for diagnosis of multiple sclerosis 2017 of different phenotypes (relapsing-remitting, primary progressive, and secondary progressive), will be recruited during their follow-up visits to our MS unit.

Exclusion Criteria:

* • Recent MS relapse or use of corticosteroids in the past 3 months

  * patients with a systemic disease like diabetes mellitus, hypertension, cardiac disease, liver or renal disease or alcoholic patients
  * patients who are on a specific diet.
  * patients using any anti-inflammatory drugs, cholesterol-lowering agents, estrogen replacement therapy, steroid therapy or other drugs that could affect the metabolic profile.
  * Patients with non-MS demyelinating disorders like NMOSD and MOGAD.
  * Patients who failed to commit to regular follow-ups.